Knocking out the stress response

Molecular Psychiatry

Volumn 4, Issue 5, 1999, Pages 403-407

  Bornstein, S R ^a   Bottner A ^b   Chrousos, G P ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CYTOKINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AUTONOMIC NERVOUS SYSTEM; GENE OVEREXPRESSION; GENETIC ENGINEERING; HYPOPHYSIS CELL; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; KNOCKOUT MOUSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; STRESS; TRANSGENIC ANIMAL;

EID: 0032746287     PISSN: 13594184     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.mp.4000602     Document Type: Short Survey

References (53)

1. 1 Chrousos GP. Stressors, Stress, and Neuroendocrine Integration of the Adaptive Response: The 1997 Hans Selye Memorial Lecture. Ann NY Acad Sci 1998; 30: 311-335.
2. 2 Majzoub JA, Muglia LJ. Knock-out mice. N Engl J Med 1996; 334: 904-907.
3. 3 Muglia L, Jacobson L, Dikkes P, Majzoub JA. Corticotropin-releasing hormone deficiency reveals major fetal but not adult glucocorticoid need. Nature 1995; 373: 427-432.
4. 4 Allen RG et al. Targeted ablation of pituitary pre-proopiamelano-cortin cells by herpes simplex virus-1 thymidine kinase differentially regulates mRNAs encoding the adrenocorticotropin receptor and aldosterone synthase in the mouse adrenal gland. Mol Endocrinol 1995; 9: 1005-1016.
5. 5 Stenzel-Poore MP, Cameron VA, Vanghan J, Sawchenko PE, Vale W. Development of Cushing's syndrome in corticotropin-releasing factor transgenic mice. Endocrinology 1992; 130: 3378-3386.
6. 6 Cole TJ et al. Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev 1995; 9: 1608-1621.
7. 7 Quaife CJ et al. Visualization and ablation of phenylthanolamine N-methyltransferase producing cells in transgenic mice. Transgenic Res 1994; 3: 388-400.
8. 8 Zhou QY, Palmiter RD. Dopamine-deficient mice are severely hypoactive, adipsic and aphagic. Cell 1995; 83: 1197-1209.
9. 9 Smith GW et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093-1102.
10. 10 Timpl P et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 1998; 19: 162-166.
11. 11 Bornstein SR, Tajima T, Eisenhofer G, Haidan A, Aguilera G. Adrenomedullary funcion is severely impaired in 21-OH-deficient mice. Faseb J 1999; 13: 1185-1194.
12. 12 Zhou QY, Quaife CJ, Palmiter RD. Targeted disruption of the tyrosine hydroxylase gene reveals that catecholamines are required for mouse fetal development. Nature 1995; 374: 640-643.
13. 13 Yano H, Readhead C, Nakashima M, Ren SG, Melmed S. Pituitary-directed leukemia inhibitory factor transgene causes Cushing's syndrome: neuro-immune-endocrine modulation of pituitary development. Mol Endocrinol 1998; 12: 1708-1720.
14. 14 Raber J, O'Shea RD, Bloom FE, Campbell IL. Modulation of hypothalamic-pituitary-adrenal function by transgenic expression of interleukin-6 in the CNS of mice. J Neurosci 1997; 17: 9473-9480.
15. 15 Turnbull AV et al. CRF type 1 receptor-deficient mice exhibit a pronouced pituitary-adrenal response to local inflammation. Endocrinology 1999; 140: 1013-1017.
16. 16 Chrousos GP. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. N Eng J Med 1998; 332: 1351-1362.
17. 17 Willenberg HS et al. Aberrant interleukin-1 receptors in a cortisol-secreting adrenal adenoma causing Cushing's syndrome. N Engl J Med 1998; 339: 27-31.
18. 18 Liu D et al. Moms, pups, glucocorticoid receptor gene expression and responses to stress. Science 1997; 277: 1659-1662.
19. 19 Heinrichs SC et al. Anti-sexual and anxiogenic behavioral consequences of corticotropin-releasing factor overexpression are centrally mediated. Psychoneuroendocrinology 1997; 22: 215-224.
20. 20 Boehme SA et al. Immunosuppressive phenotype of cortinotropin-releasing factor transgenic mice is reversed by adrenalectomy. Cell Immunol 1997; 176: 103-112.
21. 21 Stenzel-Poore MP et al. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J Neurosci 1994; 14: 2579-2584.
22. 22 Burrows HL et al. Excess corticotropin releasing hormone-binding protein in the hypothalamic-pituitary-adrenal axis in transgenic mice. J Clin Invest 1998; 101: 1439-1447.
23. 23 Lovejoy DA et al. Ectopic expression of the CRF-binding protein: minor impact on HPA axis regulation but induction of sexually dimorphic weight gain. J Neuroendocrinol 1998; 10: 483-491.
24. 24 Crawford PA, Sadovsky Y, Milbrandt J. Nuclear receptor steroidogenic factor 1 directs embryonic stem cells toward the steroidogenic lineage. Mol Cell Biol 1997; 17: 3997-4006.
25. 25 Muglia LJ et al. Expression of the mouse corticotropin-releasing hormone gene in vivo and targeted inactivation in embryonic stem cells. J Clin Invest 1994; 93: 2066-2072.
26. 26 Muglia LJ et al. Impaired diurnal adrenal rhythmicity restored by constant infusion of corticotropin-releasing hormone in corticotropin-releasing hormone-deficient mice. J Clin Invest 1997; 99: 2923-2929.
27. 27 Parker KL. The roles of steroidogenic factor 1 in endocrine development and function. Mol Cell Endocrinol 1998; 140: 59-63.
28. 28 Caron KM et al. Targeted disruption of the mouse gene encoding steroidogenic acute regulatory protein provides insights into congenital lipoid adrenal hyperplasia. Proc Natl Acad Sci USA 1997; 94: 11540-11545.
29. 29 Luo X, Ikeda Y, Parker KL. A cell-specific nuclear receptor is essential for adrenal and gonadal development and sexual differentiation. Cell 1994; 77: 481-490.
30. 30 Goloh H et al. Survival of steroid 21-hydroxylase-deficient mice without endogenous corticosteroids after neonatal treatment and genetic rescue by transgenesis as a model system for treatment of congenital adrenal hyperplasia in humans. Endocrinology 1994; 135: 1470-1476.
31. 31 Kotelevtsev Y et al. 11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proc Natl Acad Sci USA 1997; 94: 14924-14929.
32. 32 Pepin MC, Pothier F, Barden N. Impaired type II glucocorticoid receptor function in mice bearing antisense RNA transgene. Nature 1991; 355: 725-728.
33. 33 Barden N et al. Endocrine profile and neuroendocrine challenge tests in transgenic mice expressing antisense RNA against the glucocorticoid receptor. Neuroendocrinology 1997; 66: 212-220.
34. 34 Karanth S et al. Hypothalamic-pituitary-adrenocortical axis changes in a transgenic mouse with impaired glucocorticoid receptor function. Endocrinology 1997; 138: 3476-3485.
35. 35 Richard D et al. Energy balance and lipid metabolism in transgenic mice bearing an antisense GCR gene construct. Am J Physiol 1993; 265: R146-R150.
36. 36 Strohle A et al. Age-and stimulus-dependent changes in anxiety-related behaviour of transgenic mice with GR dysfunction. Neuroreport 1998; 9: 2099-2102.
37. 37 Rousse I et al. Spatial memory in transgenic mice with impaired glucocorticoid receptor function. Neuroreport 1997; 8: 841-845.
38. 38 Stec I et al. Dexamethasone nonsuppression in transgenic mice expressing antisense RNA to the glucocorticoid receptor. J Psychiatr Res 1994; 28: 1-5.
39. 39 Morale MC et al. Disruption of hypothalamic-pituitary-adrenocortical system in transgenic mice expressing type II glucocorticoid receptor antisense ribonucleic acid permanently impairs T cell function: effects on T cell trafficking and T cell responsiveness during postnatal development. Endocrinology 1995; 136: 3949-3960.
40. 40 Berger SA et al. Molecular genetic analysis of glucocorticoid and mineralocorticoid signaling in development and physiological processes. Steroids 1996; 61: 236-239.
41. 41 Kaneda N et al. Tissue-specific and high-level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron 1991; 6: 583-594.
42. 42 Kobayashi K et al. Functional and high level expression of human dopamine β-hydroxylase in transgenic mice. J Biol Chem 1994; 269: 29725-29731.
43. 43 Kobayashi K et al. Genetic alteration of catecholamine specificity in transgenic mice. Proc Natl Acad Sci USA 1992; 89, 1631-1635.
44. 44 Cadd GG et al. Alteration of neurotransmitter phenotype in noradrenergic neurons of transgenic mice. Mol Endocrinol 1992; 6: 1951-1960.
45. 45 Kobayashi K et al. Targeted disruption of the tyrosine hydroxylase locus results in severe catecholamine depletion and perinatal lethality in mice. J Biol Chem 1995; 270: 27235-27243.
46. 46 Thomas SA, Matsumoto AM, Palmiter RD. Noradrenaline is essential for mouse fetal development. Nature 1995; 374: 643-646.
47. 47 Thomas SA, Palmiter RD. Impaired maternal behavior in mice lacking norepinephrine and epinephrine. Cell 1997; 91: 583-592.
48. 48 Thomas SA, Palmiter RD. Thermoregulatory and metabolic phenotypes of mice lacking noradrenaline and adrenaline. Nature 1997; 387: 94-97.
49. 49 Thomas SA, Palmiter RD. Examining adrenergic roles in development, physiology, and behavior through targeted disruption of the mouse dopamine β-hydroxylase gene. Adv Pharmacol 1998; 42: 57-60.
50. 50 Alaniz RC et al. Dopamine beta-hydroxylase deficiency impairs cellular immunity. Proc Natl Acad Sci USA 1999; 96: 2274-2278.
51. 51 Van Dam AM et al. Interleukin 1 (IL-1) type I receptors mediate activation of rat hypothalamus-pituitary-adrenal axis and interleukin 6 production as shown by receptor type selective deletion mutants of IL-1beta. Cytokine 1998; 10: 413-417.
52. 52 Chesnokova V, Auernhammer CJ, Melmed S. Murine leukemia inhibitory factor gene disruption attenuates the hypothalamo-pituitary-adrenal axis stress response. Endocrinology 1998; 139: 2209-2216.
53. 53 Akita S, Malkin J, Melmed S. Disrupted murine leukemia inhibitory factor (LIF) gene attenuates adrenocorticotropic hormone (ACTH) secretion. Endocrinology 1996; 137: 3140-3143.